About Resolution Therapeutics
Resolution Therapeutics is a company based in Edinburgh (United Kingdom) founded in 2017 by John Campbell and Stuart Forbes. Resolution Therapeutics has raised $119.88 million across 2 funding rounds from investors including Syncona. The company has 6 employees. Resolution Therapeutics offers products and services including RTX001 and Macrophage Cell Therapies. Resolution Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 6
- Founders John Campbell, Stuart Forbes
- SectorsHealthcare
- Email••••••••
- Website resolution-tx.com
- Social LinkedIn X
- Legal Name Resolution Therapeutics Limited
- Date of Incorporation 14 Dec, 2017
- Jurisdiction LONDON, ENGLAND
- Net Profit-$4.95 M (USD)-254as on Mar 31, 2022
- EBITDA-$5.39 M (USD)-285as on Mar 31, 2022
- Total Equity Funding$119.88M (USD)
in 2 rounds
- Latest Funding Round$84.3M (USD), Series B
Oct 2024
- Investors
- Employee Count6
Products & Services of Resolution Therapeutics
Resolution Therapeutics offers a comprehensive portfolio of products and services, including RTX001 and Macrophage Cell Therapies.
Treats end-stage liver disease using regenerative macrophages for organ repair.
Addresses inflammatory organ damage through engineered cell-based treatments.
Funding Insights of Resolution Therapeutics
Resolution Therapeutics has successfully raised a total of $119.88M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $84.3 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $119.88M
- Total Rounds 2
- Last Round Series B — $84.3M
- First Round $35.58M
(Dec 2020)
- Investors Count 1
All 2 funding rounds of Resolution Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Resolution Therapeutics
Resolution Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom |
Investor details for Resolution Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Resolution Therapeutics
8 people are tracked at Resolution Therapeutics (3 in leadership, 5 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
John Campbell | Co-Founder | Leadership |
Stuart Forbes | Co-Founder | Leadership |
Edward Hodgkin | Director | Leadership |
Andrew Philip O'Leary | Senior Analytical Development Scientist | Team |
Mónica Reis | Group Leader | Team |
Mohan Lota Fcca | Finance Manager | Team |
Dimple Patel | Senior Financial Planning And Analysis Manager | Team |
Jessica Llewellyn | Senior Scientist | Team |
Complete people profiles for Resolution Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Resolution Therapeutics
3 dated milestones of Resolution Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Resolution Therapeutics is founded.
- Funding First funding round of $35.6M.
- Funding Latest funding round, Series B, of $84.3M.
Competitors of Resolution Therapeutics
Resolution Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| madrigalpharma.com | 2011 | Conshohocken, United States | $38.38M | 56 | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis |
Detailed competitors of Resolution Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Resolution Therapeutics
The website of Resolution Therapeutics (resolution-tx.com) receives about 2K visits a month.
- Monthly visits2K
▲ 63.4% vs previous month
Latest news on Resolution Therapeutics
Complete news archive for Resolution Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Resolution Therapeutics
10 companies that operate in the same segment as Resolution Therapeutics (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Resolution Therapeutics
Resolution Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Resolution Therapeutics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Resolution Therapeutics is a funded company, having raised a total of $119.88M across 2 funding rounds to date. The company's 1st funding round was a Series A of $35.58M, raised on Dec 2020.
Resolution Therapeutics has 6 employees.
Resolution Therapeutics was founded in 2017 in Edinburgh, United Kingdom, focusing on biotechnology. Cell therapies based on macrophage biology, engineering, and manufacturing processes are developed by the company. These therapies target inflammatory and liver diseases by enhancing immune responses, preventing organ damage from inflammation, aiding wound sterilization, and supporting organ repair. Operations center on proprietary platforms for therapeutic solutions in this sector.
Resolution Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Resolution Therapeutics offers RTX001 and Macrophage Cell Therapies.
Resolution Therapeutics has 1 investor. Key investors include Syncona.
Resolution Therapeutics operates through Resolution Therapeutics Limited.